

January, 2008

Name: Jean Linette Grem, M.D., F.A.C.P.

[

]

Mailing Address: University of Nebraska Medical Center
Section of Oncology/Hematology
987680 Nebraska Medical Center
Omaha NE 68198-7680
tel: 402-559-6210
fax: 402-559-6520
E-mail: jgrem@UNMC.edu

[

]

Undergraduate & Graduate Training			
Dates	University	Degree/honors	Field
9/1972 - 5/16/1976	Purdue University W. Lafayette, IN 47907-1967	B.S. With Highest Distinction	Biology
9/1976 - 6/6/1980	Jefferson Medical College 1025 Walnut St Philadelphia PA 19107-5083	M.D. Cum Laude	Medicine
7/1/1980 - 6/30/1983	University of Iowa Hospitals & Clinics 200 Hawkins Drive Iowa City, Iowa 52242	Internship & Residency	Internal Medicine
7/1/1983 - 6/30/1985 7/1985 - 6/1986	University of Wisconsin Clinical Cancer Center, 600 Highland Ave. K5/601 Madison, WI 53792-6164	Clinical Fellowship & Research Fellowship	Medical Oncology

**APPEARS THIS WAY
ON ORIGINAL**

Professional Appointments		
Dates	Position	Location
7/86 - 2/89	Senior Investigator, Developmental Chemotherapy Section, Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute (Executive Plaza North)	Bethesda, MD
2/89 - 1/92	Senior Investigator, Medicine Branch, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute (NIH Clinical Center)	Bethesda, MD
2/92 - 11/96	Senior Investigator, NCI-Navy Medical Oncology Branch, Clinical Oncology Program, Division of Cancer Treatment (National Naval Medical Center)	Bethesda, MD
7/92	Promotion with scientific tenure to GM-14 (<i>equivalent to associate professor status</i>)	
12/96 - 7/01	Head, Cellular & Clinical Pharmacology Section, Developmental Therapeutics Department, Medicine Branch, Division of Clinical Sciences, National Cancer Institute (National Naval Medical Center)	Bethesda, MD
10/98	Promotion to GM-15 (<i>equivalent to professor status</i>)	
12/96-10/98	Acting Chair, Developmental Therapeutics Department	
7/01 - 9/26/03	Head, Gastrointestinal Malignancies Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute (National Naval Medical Center)	Bethesda, MD
10/03 - present	Professor of Medicine, U. Nebraska Medical Center, Department of Internal Medicine, Section of Hematology/Oncology	Omaha, NE
12/03 - present	Associate Director for Translational Research, Eppley Cancer Center	

Honors:

Undergraduate:

- 1) member Phi Beta Kappa Honor Society (Junior Year)
- 2) member Phi Kappa Phi Honor Society
- 3) recipient of the Alpha Lambda Delta Book Award for distinguished scholarship
- 4) recipient of Alpha Zeta Delta "Purdue Top Female Scholar Award"

Graduate:

- 1) member of Alpha Omega Alpha Honor Society
- 2) recipient of AMWA's scholarship achievement citation
- 3) recipient of the C.V. Mosby Company Book prize for scholastic achievement

Professional:

- 1) Recipient, DHHS/NIH Special Achievement Award, 1990
- 2) Awarded Fellowship in the American College of Physicians, 1993
- 3) Recipient of a Plaque from the Division of Clinical Sciences, June, 1996 in recognition for dedication and commitment in helping the Division of

- 4) Clinical Sciences achieve its mission
Pfizer Distinguished Visiting Professor of Medical Oncology, Uniformed Services University of the Health Sciences, Bethesda, MD June 29-30, 2006

Medical Licensure

1981 Iowa (inactive: # _____): 07/29/1981 - 10/01/1985
1983 Wisconsin (inactive: # _____): 07/01/1983 - 10/30/2003
2003 Nebraska (active: # _____): 1/8/2003-10/01/2006

DEA: []
UPIN: []
NPI: []

Medical Specialty Boards:

7/1/1981 National Board of Medical Examiners (# _____)
9/14/1983 Diplomate, American Board of Internal Medicine (# _____)
11/19/1985 Diplomate, Medical Oncology, American Board of Internal Medicine (# _____)

Research Support During Oncology Fellowship

Fellow of the American Cancer Society. Period of Support, 7/1/83-6/30/85.
Recipient of a Research Fellowship from the Pearl M. Stetler Fund. Period of support, 7/1/85-6/30/86.

Funding at UNMC

1. UNMC Clinical Research Center Research Support Fund for IRB 035-04: "A Phase II Study of Neo-Adjuvant Chemotherapy and Radiation in Patients with Locally Advanced Pancreatic Cancer"
J. Grem, Principal Investigator. Grant MXH/99-925-1279: funded May, 2004; Status: Ongoing

DHHS/NIH/NCI Research Supplement to Spore in Gastrointestinal Cancer: "A Phase II Study of Neo-Adjuvant Chemotherapy and Radiation in Patients with Locally Advanced Pancreatic Cancer"
J. Grem, Project Leader. Grant 34-1905-2141-331: funded September, 2004; Status: Ongoing
2. UNMC Clinical Research Center Research Support Fund for IRB 170-04: "A Phase I and Pharmacologic Study of 17-(Allylamino)-17-demethoxygeldanamycin (AAG, NSC 330507) in Adult Patients with Solid Tumors". J. Grem, Principal Investigator. Grant MXH/99-925-1281: funded August, 2004; Status: Ongoing
3. UNMC Clinical Research Center Research Support Fund for IRB 285-04: "A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients". J. Grem, Principal Investigator. Grant MXH/99-925-1267: Funded October, 2004; Status: Ongoing
4. _____ : "Phase II Trial of _____ in Combination with _____ in Patients with Advanced Gastrointestinal Cancers with Varying Degrees of Renal Impairment". J. Grem, Principal Investigator. Grant _____ funded March, 2004
Completed: 2006
5. _____ "A Phase I Safety, Pharmacodynamic, Anti-tumor Activity, and Pharmacokinetic Study of _____ Alone and in Combination with _____ in Patients with Advanced Solid Tumors". J. Grem, Principal Investigator. Grant _____ ; funded October, 2005; Status:

Ongoing

6. _____ "A multi-center open-label Phase I study evaluating the safety and tolerability of intravenous _____ in combination with intravenous _____ in the treatment of advanced and/or metastatic solid tumors and lymphoma". J. Grem, Principal Investigator. Grant _____; funded, August, 2006. Status: Ongoing

7. Eastern Cooperative Oncology Group: E4203 "Phase II study of treatment selection based upon tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer." J. Grem, Principal Investigator. Grant 36-5234-2212-001; funded, August, 2006; Status: Ongoing

8. Frontier Science & Technology Research Foundation, Inc.: "Laboratory studies for ECOG Protocol E4203". J. Grem, Principal Investigator. Grant 36-5234-2213-001; funded, August, 2006.; Status: Ongoing

9. _____ "A phase 2 study of _____ in combination with _____ for the treatment of pancreatic cancer". J. Grem, Principal Investigator. Grant _____ funded, J. Grem, Principal Investigator. Grant _____ . July, 2007. Status: Ongoing

Membership in Professional Societies

- Fellow, American College of Physicians (Member # _____)
- Member, American Society of Clinical Oncology (Member # _____)
- Member, American Association for Cancer Research (Member # _____)
- Member, Phi Beta Kappa
- Member, Alpha Omega Alpha
-

Professional Activities:

- Chairperson, Clinical Pharmacology Subcommittee, ASCO Program Committee, 1992.
- Member, Toxicity Monitoring Committee, "NSABP protocol C-05, An adjuvant study of 5-fluorouracil and leucovorin ± interferon alfa-2a in Dukes B and C Colon Cancer", 1992-1993
- Member, PDQ External Advisory Board, 9/94 to 9/99
- Co-Chairperson, Experimental Therapeutics Poster Discussion Session, AACR, March 22, 1995
- Guest Member, Gastrointestinal Tumor Committee, NSABP, 1996
-
- Member, Division of Clinical Science's Clinical Research Advisory Group to Dr. _____
Division Director, 10/95 to 6/96
- Member, 1996 Rosenthal Award Subcommittee, American Association for Cancer Research, Inc.
- Invited Participant, "Third International Workshop on Pharmacodynamics of Anticancer Agents", Sept. 13-17, 1995, Irvington, VA.
- Invited Guest Expert, FDA's Antiviral Drugs Advisory Committee: June 6, 1996 meeting on sorivudine
- Voting member, NCI's Drug Decision Network, 1/97 to 11/98
- Invited Participant: _____ in Colorectal Cancer-Experts Meeting, Nov. 15, 1997, New York, NY
- Invited Discussant: Symposium on Colorectal Cancer, Feb. 26-27, Memorial Sloan Kettering Cancer Center, New York, NY
- Invited Participant: "Fourth International Workshop on Pharmacodynamics of Anticancer Agents", Aug. 25-29, 1998, Dunkeld, Scotland, UK
- Invited Chairperson, _____ Regional Advisory Board, Oct. 16-17, 1998, New York, NY
- Invited Participant: _____ in Colorectal Cancer-Experts Meeting, Nov. 14, 1998, New York, NY
- Invited Participant: Cancer Therapy Evaluation Program's meeting on Common Data Elements for Phase III Clinical Trials, July 14, 1999, Rockville, MD

- Invited Participant: NCI Colorectal Cancer Progress Review Group Roundtable, Jan. 5-7, 2000, San Francisco, CA
- Invited Participant: First U.S. ——— Investigator's Meeting, Feb. 11-12, 2000, Las Vegas, NV
- Invited Participant: Perspective on Fluorinated Pyrimidine Use in Breast and Gastrointestinal Oncology, April 16-17, 2000, New York, NY.
- Member, ASCO Program Committee, Gastrointestinal Cancers (08/00-08/02)
- Invited Participant: "Fifth International Workshop on Pharmacodynamics of Anticancer Agents", Sept. 30-Oct. 3, 2001, Sea Island, GA
- Voting Consultant, FDA's Oncologic Drugs Advisory Committee, Dec 7, 2001: Post-marketing Safety Issues with Irinotecan/fluorouracil/leucovorin, Silver Spring, MD
- Co-Chair, Gastrointestinal Cancer Poster Discussion Session, ASCO, May 19, 2002, Orlando, FL
- Consultant: FDA Center for Drug Evaluation and Research, NDA 21-492 (sponsor: Sanofi-Synthelabo) for Eloxatin (oxaliplatin) for Injection for the treatment of patients with metastatic colorectal carcinoma who have progressed on or after treatment with irinotecan + bolus 5-FU/LV.
- Associate Team Leader: Colorectal Disease Site Team for the American College of Surgeons Commission on Cancer. Term: 2002-present.
- Invited Consultant: ——— Neurotoxicity Advisory Board. Jan 20, 2004, San Francisco, CA
- Invited Participant, "Sixth International Workshop on Pharmacodynamics of Anticancer Agents", Nov 7-10, 2004, Venice, Italy
- Member, National Comprehensive Cancer Network, Panel Member for Colon Cancer, Rectal Cancer, and Anal Cancer; 2004-present.
- Member, Pharmacy and Therapeutics Committee, UNMC, February, 2005 - present
- Member, Gastrointestinal Cancer-Colorectal/Liver: ASCO Program Committee for ASCO 2006 Annual Meeting Scientific Program
- Member, Medical Advisory Committee, Colorectal Cancer Subgroup, Every Woman Matters, Nebraska Office of Women's Health, 2006 - present
- Invited Advisor/Consultant: Center for Drug Evaluation and Research, Office of Oncology Drug Products, Division of Biologic Oncology Products, FDA: Post-Marketing Commitments for Biologic License Application for ERBITUX® (STN BL 125084) [cetuximab]. Fall, 2005 - Summer, 2006
- Track Leader, Gastrointestinal Cancer: Colorectal/Liver, ASCO Program Committee for ASCO 2007 Annual Meeting Scientific Program

Participation in Peer Review Process

Invited Reviewer of grant applications:

- Dutch Cancer Society
- International Human Frontiers Science Program (Bureaux Europe, 20 place des Halles, 67080, Strasbourg, Cedex, France)
- National Medical Research Council, Singapore, China
- Associazione Italiana per la Ricerca sul Cancro, Milan, Italy
- Irish Cancer Society
- Cancer Society of New Zealand, Inc.
- Singapore Cancer Society
- NCI Center for Scientific Review: Developmental Therapeutics Study Section (Fall, 2005-Fall, 2007)
- 2006 CALGB Foundation Junior Faculty Research and Investigator Awards Applicants
- NCI Cancer Center Support Grant Site Visit for Yale Cancer Center, Yale University: P30 CA016359-29. October 25-27, 2006

Invited Reviewer of Manuscripts for the following Journals:

Annals of Internal Medicine

Biochemical Pharmacology
British Journal of Cancer
British Journal of Pharmacology
Cancer
Cancer Chemotherapy and Pharmacology
Cancer Letters
Cancer Immunology and Immunotherapy
Cancer Research
Clinical Cancer Research
European Journal of Cancer
Journal of Biological Response Modifiers
Journal of Cell Cloning
Journal of Clinical Oncology
Journal of Complementary & Alternative Medicine
Journal of Interferon Research
Journal of the National Cancer Institute
International Journal of Cancer
Investigational New Drugs
Oncology
Oncology Research

Editorial Positions

Member, Editorial Board, *Journal of the National Cancer Institute*, 6/1992 - 5/1999
Member, Editorial Board, *International Journal of Oncology*, 1/1995 - 1/1997
Associate Editor, *Clinical Cancer Research*, 1/1999 - present
Associate Editor, *Journal of the National Cancer Institute*, 5/1999 - present
Member, Editorial Board, *Cancer Chemotherapy and Pharmacology*, 9/2000 - present
Co-Editor, *Colorectal Cancer Index and Reviews* 5/2004 -present
Member, Editorial Board, *Journal of Clinical Oncology*, 1/2008-present

**APPEARS THIS WAY
ON ORIGINAL**

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

1. Metzger, W. J., Grem, J., Halverson, P. C., Sharath, M. D., Shulan, D. J., Lawton, W., and Weiler, J. M. C1 INH deficiency and angioedema: a spectrum of disease. Part one, *Ann Allergy*. 52: 269-71, 1984.
2. Metzger, W. J., Grem, J., Halverson, P. C., Sharath, M. D., Shulan, D. J., Lawton, W., and Weiler, J. M. C1 INH deficiency and angioedema: a spectrum of disease. Part two, *Ann Allergy*. 52: 285-90, 1984.
3. Grem, J.L. and Fischer, P.H. Augmentation of 5-fluorouracil cytotoxicity by dipyridamole in human colon cancer cells. *Cancer Res* 45: 2967-2792, 1985.
4. Grem, J.L., Burgess, J., and Trump, D.L. Clinical features of intramedullary spinal cord metastasis. *Cancer* 56: 2305-2314, 1985.
5. Grem, J.L., Neville, A., Smith, S., Gould, H.J., Love, R.L., and Trump, D.L. Massive skeletal muscle invasion in lymphoma. *Arch Int Med* 145: 1818-1820, 1985.
6. Grem, J.L., Merritt, J.A., and Carbone, P.P. Treatment of mitomycin-C associated microangiopathic hemolytic anemia with vincristine. *Arch Int Med* 146: 566-568, 1986.
7. Grem, J.L., Hafez, G.R., Brandenburg, J.H., and Carbone P.P. Spontaneous remission in diffuse large cell lymphoma. *Cancer* 57: 2042-2044, 1986.
8. Grem, J.L. and Trump, D.L. Reversible increase in serum alpha-fetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma. *J Clin Oncol* 4: 41-45, 1986.
8. Grem, J.L. and Fischer, P.H. Modulation of fluorouracil metabolism and cytotoxicity by nitrothiobenzylinosine. *Biochem Pharmacol* 35: 2651-2654, 1986.
9. Grem, J.L., Robins, H.I., Wilson, K.S., Gilchrist, K., and Trump, D.L. Metastatic Leydig cell cancer - report of three cases and review of the literature. *Cancer* 58: 2116-2119, 1986.
10. Grem, J.L. and Fischer, P.H. Alteration of fluorouracil metabolism in human colon cancer cells with a selective increase in fluorodeoxyuridine monophosphate levels. *Cancer Res* 46: 6191-6199, 1986.
11. Grem, J.L., Tutsch, K.D., Simon, K.J., Alberti, D.B., Willson, J.K.V., Tormey, D.C., Swaminathan, S., and Trump, D.L. Phase I study of taxol (NSC 125973) administered as a short I.V. infusion daily for 5 days. *Cancer Treat Rep* 71:1179-1184, 1987.
12. Grem, J.L., Shoemaker, D.D., Hoth, D.F., King, S.A., Plowman, J., Zaharko, D., Grieshaber, C.K., Harrison Jr., S.D., Cradock, J.C., and Leyland-Jones, B. Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials. *Inv New Drugs* 5:315-328, 1987.
13. Grem, J.L., Hoth, D.F., Hamilton, J.M., King, S.A., Leyland-Jones, B. Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic Acid. *Cancer Treat Rep* 71:1249-1264, 1987.
14. Trump, D.L., Grem, J.L., Tutsch, K., Willson, J.K.V., Simon, K.J., Alberti, D., Storer, B., and Tormey, D.C. Platinum analogue combination chemotherapy - a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. *J Clin Oncol* 5:1281-1289, 1987.

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

15. Grem, J.L., Shoemaker, D.D., Petrelli, N.J., and Douglass Jr., H.O. Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma. *Cancer Treat Rep* 71: 1122, 1987 (letter).
16. Grem, J.L., Hoth, D.F., Leyland-Jones, B., King, S.A., Ungerleider, R.S., and Wittes, R.E. Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases. *J Clin Oncol* 6:351-379, 1988.
17. Grem, J.L., King, S.A., Wittes, R.E., Leyland-Jones, B. The role of methotrexate in osteosarcoma. *J Natl Cancer Inst* 80:626-656, 1988.
18. Grem, J.L., Falkson, G., Love, R.R., and Tormey, D.C. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma: an Eastern Cooperative Oncology Program Group Pilot Study. *Am J Clin Oncol*, 11:528-534, 1988.
19. Grem, J.L., King, S.A., O'Dwyer, P.J., and Leyland-Jones, B. N-(Phosphonoacetyl)-L-Aspartate (PALA): a review of its biochemistry and clinical activity. *Cancer Res*, 48:4441-4454, 1988.
20. Grem, J.L., Cheson, B.D., King, S.A., Leyland-Jones, B., and Suffness, M. Cephalotaxine esters: antileukemic advance or therapeutic failure? *J Natl Cancer Inst*, 80: 1095-1103, 1988.
21. Grem, J.L., Ellenberg, S.S., King, S.A., and Shoemaker, D.D. Correlates of severe or life-threatening toxicity from trimetrexate. *J Natl Cancer Inst* 80:1315-1317, 1988.
22. Grem, J.L., Mulcahy, R.T., Miller, E.M., Allegra, C.J., and Fischer, P.H. Interaction of deoxyuridine with fluorouracil and dipyridamole in a human colon cancer cell line. *Biochem Pharmacol* 38: 51-59, 1989.
23. Grem, J.L., King, S.A., Cheson, B.D., Leyland-Jones, B., and Wittes, R.E. 2'-Deoxycoformycin in hairy cell leukemia: treatment by the special exception mechanism. *J Natl Cancer Inst* 81: 448-453, 1989.
24. O'Dwyer, P.J., King, S.A., Eisenhauer, E., Grem, J.L., and Hoth, D.F. Hypersensitivity reactions to deoxycoformycin. *Cancer Chemother Pharmacol* 23:173-175, 1989.
25. Willson J.K.V., Fischer P.H., Remick S.C., Tutsch K.D., Grem, J.L., Nieting L., Alberti D., Bruggink, J., and Trump, D.L. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. *Cancer Res* 49: 1866-1889, 1989.
26. Grem, J.L. and Allegra, C.J. Cytotoxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. *J Natl Cancer Inst*, 81: 1413-1417, 1989.
27. Durrleman, S., Grem, J.L., and Cheson, B.D. 2'-Deoxycoformycin after failure of alpha-interferon in hairy cell Leukemia. *Eur J Hem*, 43: 297-302, 1989.
28. Grem, J.L., King, S.A., Costanza, M.E., and Brown, T.D. Hypersensitivity Reactions to Trimetrexate. *Inv New Drugs*, 8: 211-214, 1990.
29. Grem, J.L., Rubinstein, L., King, S.A., Hawkins, M.J., Cheson, B.D., and Shoemaker, D.D. Clinical toxicity associated with Tiazofurin. *Inv New Drugs*, 8: 227-238, 1990.

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

30. Abbruzzese, J.L., Weeks, A., Raber, M.N., Gravel, D., DuBrow, R.A., Levin, Grem, J., and Chun, H.G. A Phase I trial of methyl-CCNU plus weekly 5-fluorouracil and high-dose leucovorin in patients with advanced colorectal cancer. *J Natl Cancer Inst*, 81: 1840-1842, 1989.
31. Remick, S.C., Grem, J.L., Fischer, P.H., Tutsch K.D., Alberti D.B., Nieting, L.M., Tombes, M.B., Bruggink, J., Willson, J.K.V., and Trump, D.L.: A Phase I trial of 5-Fluorouracil and dipyridamole administered by 72-hour concurrent continuous infusion. *Cancer Res*, 50:2667-2672, 1990
32. Grem, J.L., Plowman, J., Rubinstein, L., Hawkins, M.J., and Harrison, S.D. Jr. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model. *Leukemia Res* 15:229-236, 1991.
33. Grem, J.L. and Allegra, C.J. Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and cytosine arabinoside by cyclopentenyl cytosine. *Cancer Res* 50:7279-7284, 1990.
34. Grem, J.L., King, S.A., Sorensen, J.M., and Christian, M.C. Clinical use of thymidine as a rescue agent from methotrexate Toxicity. *Inv New Drugs* 9:281-290, 1991.
35. Grem, J.L. and Allegra, C.J. Sequence-dependant interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1- β -d-arabinofuranosylcytosine. *Biochem Pharmacol* 42:409-418, 1991.
36. Grem, J.L., O'Dwyer, P.J., Elson, P., Simon, N., Trump, D.L., Falkson, G., Frontiera, M., and Vogel, S. Cisplatin, carboplatin and cyclophosphamide combination chemotherapy in advanced stage ovarian carcinoma: an Eastern Cooperative Oncology Group Pilot Study. *J Clin Oncol*, 9:1793-1800, 1991.
37. Schiller, J.H., Storeer, B.E., Witt, P.L., Alberti, D., Tombes, M.B., Arxoomanian, R., Proctor, R.A., McCarthy, D., Brown, R.R., Voss, S.D., Remick, S.C., Grem, J.L., Borden, E.C., and Trump, D.L. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times Weekly. *Cancer Res* 51:1651-1658, 1991.
38. Grem, J.L., McAtee, N., Balis, F., Murphy, R., Steinberg, S., Gay, L., Caubo, K., Hamilton, M., Sorenson, M., Sartor, O., Goldstein, L., Goldspiel, B., and Allegra, C.J. A pilot study of Interferon alfa-2a in combination with 5-fluorouracil and plus high-dose leucovorin in metastatic gastrointestinal carcinoma. *J Clin Oncol*, 9:1811-1820, 1991.
39. Grem, J.L., King, S.A., Chun, H.G., and Grever, M.J. Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy. *Am J Hem*, 38:245-247, 1991.
40. Yee, L.K., Allegra, C.J., and Grem, J.L. Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cell lines. *Biochem Pharmacol* 43:1587-1599, 1992.
41. Blaney, S., Balis, F.M., Grem, J., Cole, D.E., Adamson, P.C., Poplack, D.G. Modulation of the cytotoxic effect of cyclopentenylcytosine by its primary metabolite, cyclopentenyl uridine. *Cancer Res* 52:3503-3505, 1992.
42. Yee, L.K. Allegra, C.J., Steinberg, S.M., and Grem, J.L. Decreased catabolism of 5-fluorouracil in peripheral blood mononuclear cells during therapy with 5-fluorouracil, leucovorin, and interferon α -2a. *J Natl Cancer Inst* 84:1820-1825, 1992.
43. Bailey, H., Wilding, G., Tutsch, K.D., Arzoomanian, R.Z., Alberti, D., Tombes, M.B., Grem, J.L., and Spriggs, D.R. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

- concurrent 120-h continuous infusions. *Cancer Chemother Pharmacol* 30:297-302, 1992.
44. Blaney, S.M., Grem, J.L., Balis, F.M., Cole, D.E., Adamson, P.C., Poplack, D.G. Mechanism of resistance to cyclopentenyl cytosine in Molt-4 lymphoblasts. *Biochem Pharmacol*, 45:1493-1501, 1993 .
 45. Grem, J.L., McAtee, N., Balis, F., Murphy, R., Venzon, D., Kramer, B., Goldspiel, B., Begley, M., and Allegra, C.J. A Phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. *Cancer*, 72:663-668, 1993.
 46. Grem, J.L., Jordan, E., Robson, M.E., Binder, R.A., Hamilton, J.M., Steinberg, S.M., Arbuck, S.G., Beveridge, R.A., Kales, A.N., Miller, J.A., Weiss, R.B., McAtee, N., Chen, A., Goldspiel, B., Sover, E., Bastian, A., Allegra, C.J. A Phase II study of 5-fluorouracil, leucovorin and interferon α -2a in metastatic colorectal carcinoma. *J Clin Oncol*, 11:1737-1745, 1993.
 47. Agbaria, R., Ford, H. Jr., Kelley, J.A., Xie, F., Politi, P., Grem, J.L., Cooney, D.A., Marquez, V.E., Allegra, C.J., and Johns, D.G. Measurement of cyclopentenyl cytosine 5'-triphosphate in vitro and in vivo by multidimensional high performance liquid chromatography. *Analyt Biochem*, 213:90-96, 1993.
 48. Grem, J.L., Drake, J.C., and Allegra, C.J. Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography. *Anticancer Drugs* 4:545-554, 1993.
 49. Grem, J.L., McAtee, N., Steinberg, S., Murphy, R., Drake, J., Chisena, T., Hamilton, J.M., Arbuck, S., Balis, F., Cysyk, R., Goldstein, L., Sorensen, J.M., Chen, A., Setser, A., Jordan, E., Goldspiel, B., Carvalho, M., and Allegra, C.J. A Phase I study of continuous infusion 5-Fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal carcinoma. *Cancer Res* 53:4828-4836, 1993.
 50. Chu, E., Takimoto, C., Voeller, D., Grem, J.L., and Allegra, C.J. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. *Biochemistry*, 32:4756-4760, 1993.
 51. Grem, J.L., McAtee, N., Murphy, R.F., Balis, F.M., Steinberg, S., Hamilton, J.M., Arbuck, S.G., Setser, A., Jordan, E., Chen, A., Kohler, D., Kotite, B., and Allegra, C.J. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. *J Clin Oncol* 12:560-568, 1994.

APPEARS THIS WAY
ON ORIGINAL

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

52. Takimoto, C.H., Klecker, R.W., Dahut, W.L., Yee, L.K., Strong, J.M., Allegra, C.J., and Grem, J.L. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid phase extraction and HPLC. *J Chromatog B*, 655:97-104, 1994.
53. Grem, J.L., Voeller, D.M., Geoffroy, F., Horak, E., Johnston, P.G., Allegra, C.J. Determinants of trimetrexate lethality in human colon cancer cells. *Br J Cancer* 70: 1075-1084, 1994.
54. Grem, J.L., Daychild, P., Drake, J., Geoffroy, F., Trepel, J., Pirnia, F., and Allegra, C.J. Cytotoxicity and Metabolism of 4-Methoxy-8-(β -D-ribofuranosylamino)pyrimido-[5,4-d]pyrimidine in HCT 116 Colon Cancer Cells. *Biochem Pharmacol* 48: 2117-2126, 1994.
55. Geoffroy, F., Allegra, C.J., and Grem, J.L. Enhanced cytotoxicity with interleukin-1 α and 5-fluorouracil in HCT 116 colon cancer cells. *Oncol Res* 6: 581-591, 1994.
56. Politi, P.M., Xie, F., Dahut, W., Ford, H. Jr., Kelley, J.A., Bastian, A., Setser, A., Allegra, C.J., Chen, A.P., Hamilton, J.M., Arbusk, S.G., Linz, P., Brammer, H., and Grem, J.L. Phase I clinical trial of continuous infusion cyclopentenyl cytosine. *Cancer Chemother Pharmacol* 36: 513-523, 1995.
57. Köhne, C-H., Hiddemann, W., Schüller, J., Weiss, J., Lohrmann, H-P., Schmitz-Hübner, U., Bodenstern, H., Schöber, C., Wilke, H., Grem, J., and J. Schmoll, H-J. Failure of orally administered dipyridamole to enhance the antineoplastic activity of 5-fluorouracil in combination with folinic acid in patients with advanced colorectal cancer. A prospective randomized trial. *J Clin Oncol* 13: 1201-1208, 1995.
58. Alexander, H.R., Grem, J.L., Hamilton, J.H., Pass, H.I., Hong, M., Fraker, D.L., Steinberg, S.M., McAtee, N., Allegra, C.J., and Johnston, P.G. Thymidylate synthase protein expression. Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. *Cancer J Sci Am.* 1: 49-54, 1995.
59. Grem, J.L., Geoffroy, F., Politi, P., Cuddy, D., Ross, D.D., Nguyen, D., and Allegra, C.J. Determinants of sensitivity to 1- β -D-arabinofuranosylcytosine in human colon carcinoma cell lines. *Mol Pharmacol* 48: 305-315, 1995.
60. Geoffroy, F., Dahut, W., Takimoto, C.H., and Grem, J.L. Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples. *Clin Cancer Res* 1: 1345-1351, 1995.
61. Dahut, W., Harold, N., Takimoto, C., Allegra, C., Chen, A., Hamilton, J.M., Arbusk, S., Sorensen, J.M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, W., and Grem, J. A Phase I and pharmacologic study of 9-aminocamptothecin given by seventy-two hour infusion in adult cancer patients. *J Clin Oncol* 14: 1236-1244, 1996.
62. Grem, J.L., Politi, P.M., Berg, S.L., Benckekroun, N.M., Patel, M., Balis, F.M., Sinha, B.K., Dahut, W., and Allegra, C.J. Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. *Biochem Pharmacol* 15: 1649-1659, 1996.
63. Takimoto, C.H., Lu, Z-H., Zhang, R. Liang, M.D., Larson, L.V., Cantilena, L.R. Jr., Grem, J.L., Allegra, C.J., Diasio, R.B., and Chu, E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. *Clin Cancer Res* 2: 477-482, 1996.
64. Yu, B., Carrasquillo, J., Milenic D., Chung, Y., Perentesis, P., Feuerstein, I., Eggensperger, D.,

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

- Qi, C-F., Paik, C., Reynolds, J., Grem, J., Curt, G., Siler, K., Schlom, J., and Allegra, C. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. *J Clin Oncol* 14: 1798-1809, 1996.
65. Johnston, P.G., Geoffroy, F., Drake, J., Voeller, D., Grem, J.L., and Allegra, C.J. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. *Eur J Cancer* 32A:2148-2154, 1996.
66. Grem, J.L., Yee, L.K., Venzon, D.J., Takimoto, C.H., and Allegra, C.J. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. *Cancer Chemother Pharmacol* 40: 117-125, 1997.
67. Ren, Q-F., Van Groeningen, C.J., Geoffroy, F., Allegra, C.J., Johnston, P.G., and Grem, J.L. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells. *Oncol Res* 9:77-88, 1997.
68. Takimoto, C.H., Dahut, W., Marino, M.T., Nakashima, H., Liang, M.D., Harold, N., Lieberman, R., Arbuck, S.G., Band, R.A., Chen, A.P., Hamilton, J.M., Cantilena, L.R., Allegra, C.J., and Grem, J.L. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. *J Clin Oncol* 15: 11492-11501, 1997.
69. Grem, J.L. Mcatee, N. Murphy, R.F., Balis, F.M., Cullen, E., Chen, A.P., Hamilton, J.M., Steinberg, S.M., Quinn, M., Sorensen, J.M., Arbuck, S.G., Lawrence, D., Pang, J., and Allegra, C.J. A phase I study of interferon γ -1b in combination with fluorouracil, leucovorin, and interferon α -2a. *Clin Cancer Res* 3: 1125-1134, 1997.
70. Katsafanas G.C., Grem, J.L., Blough, H.A., Moss, B. Inhibition of vaccinia virus replication by N-(phosphonacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool. *Virology* 236:177-187, 1997.
71. Ismail, A-S.A., Van Groeningen, C.J., Hardcastle, A., Ren, Q-F., Aherne, G.W., Geoffroy, F., Allegra, C.J., and Grem, J.L. Modulation of fluorouracil cytotoxicity by interferons α and γ . *Mol Pharmacol* 53: 252-261, 1998.
72. Grem, J.L., Steinberg, S.M., Chen, A.P., McAtee, N., Cullen, E., Hamilton, J.M., and Allegra, C.J. The utility of monitoring carcinoembryonic antigen during systemic therapy for advanced colorectal cancer. *Oncol Rep* 5: 559-567, 1998.
73. Ren, Q-F., Kao, V., and Grem, J. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT29 colon cancer cells. *Clin Cancer Res* 4:2811-2818, 1998.
74. Wolmark, N., Bryant, J., Smith, R., Grem, J., Allegra, C., Hyams, D., Atkins, J., Dimitrov, N., Oishi, R., Prager, D., Fehrenbacher, L., Romond, E., Colangelo, L., and Fisher, B., Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol C-05. *J Natl Cancer Inst.* 90: 1810-1816, 1998.
75. Grem, J.L., Nguyen, D., Monahan, B.P., Kao, V., and Geoffroy, F.J. Sequence-dependant antagonism between fluorouracil and paclitaxel in human breast cancer cells. *Biochem Pharmacol* 58: 477-486, 1999.

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

76. Takimoto, C.H., Yee, L.K., Venzon, D., Schuler, B., Grollman, F., Chabuk, C., Hamilton, J.H., Chen, A.P., Allegra, C.J., and Grem, J. High inter- and inpatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. *Clin Cancer Res* 5: 1347-1352, 1999.
77. Shapiro, J.D., Harold, N., Takimoto, C., Hamilton, J.M., Vaughn, D., Chen, A., Steinberg, S.M., Liewehr, D., Allegra, C., Monahan, B., Lash, A., Grollman, F., Fleming, D., Behan, K., Johnston, P.G., Haller, D., Quinn, M., Morrison, G., and Grem, J.L. A Pilot study of interferon α -2a, fluorouracil and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. *Clin Cancer Res* 5: 2399-2408, 1999.
78. Grem, J.L., Sorensen, J.M., Cullen, E. Takimoto, C.H., Steinberg, S.M., Chen, A.P., Hamilton, J.M., Arbut, S.G., McAtee, N., Lawrence, D., Goldspiel, B., Johnston, P.G., and Allegra, C.J. A phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. *Clin Cancer Res* 5: 2381-2391, 1999.
79. Hudes, G.R., Lipsitz, S., Grem, J., Morrissey, M., Weiner, L., Kugler, J. W., and Benson, A., 3rd. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292). *Cancer* 85:290-294, 1999
80. Takimoto, C.H., Morrison, G., Harold, N., Quinn, M., Monahan, B.P., Band, R.A., Cottrell, J., Guemei, A., Llorens, V., Hehman, H., Ismail A-S., Flemming, D., Gosky, D.M., Hirota, H., Berger, S.J., Berger, N.A., Chen, A.P., Shapiro, J.D., Arbut, S.G., Wright, J., Hamilton, J.M., Allegra, C.J., and Grem, J.L. A Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. *J Clin Oncol* 18: 659-667, 2000.
81. Voeller D.M., Grem, J.L., Pommier, Y., Paull, K., and Allegra, C.J. Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. *Cancer Chemother Pharmacol* 45: 409-416, 2000.
82. Bi, D., Anderson, L. W., Shapiro, J., Shapiro, A., Grem, J. L., and Takimoto, C. H. Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase, *J Chromatog B, Biomed Sci Appl* 738: 249-58, 2000.
83. Grem, J.L., Harold, N., Shapiro, J., Bi, D-Q., Quinn, M.G., Zentko, S., Keith, B., Hamilton, J.M., Monahan, B.P., Donavan, S., Grollman, F., Morrison, G., and Takimoto, C.H. A phase I and pharmacokinetic trial of weekly oral 5-fluorouracil given with eniluracil and low-dose leucovorin. *J Clin Oncol* 18: 3952-3963, 2000.
84. Grem, J.L., Quinn, M., Ismail, A.S., Takimoto, C.H., Lush, R., Liewehr, D. J., Steinberg, S.M., Balis, F.M., Chen, A.P., Monahan, B.P., Harold, N., Corse, W., Pang, J., Murphy, R.F., Allegra, C.J., and Hamilton, J.M. Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. *Cancer Chemother Pharmacol* 47: 117-125, 2001.
85. Grem, J. L., Danenberg, K. D., Behan, K., Parr, A., Young, L., Danenberg, P. V., Nguyen, D., Drake, J., Monks, A., Allegra, C. J. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's anticancer drug screen. *Clin Cancer Res* 7:999-1009, 2001.
86. Agnew, E.B., Wilson, R.H., Grem, J.L., Neckers, L., Bi, D-Q., and Takimoto, C.H. Measurement of the novel antitumor agent 17-allylamino-17-desmethoxy-geldanamycin (AAG) in human plasma

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

- using high performance liquid chromatography. *J Chromatog B, Biomed Sci Appl*, 755: 237-243, 2001.
87. Guemei, A.A., Cottrell, J., Band, R., Hehman, H., Prudhomme, M., Pavlov, M.V., Grem, J.L., Ismail, A.S., Bowen, D., Taylor, R.E., and Takimoto, C.H. Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. *Cancer Chemother Pharmacol* 47: 283-290, 2001.
 88. Thomas, R., Dahut, W., Harold, N., Grem, J.L., Monahan, B.P., Liang, M., Band, R.A., Cottrell, J., Llorens, V., Smith, J.A., Corse, W., Arbuck, S.G., Wright, J., Chen, A.P., Shapiro, J.D., Hamilton, J.M., Allegra, C.J., and Takimoto, C.H. A Phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-hour infusion weekly to adult cancer patients. *Cancer Chemother Pharmacol* 48: 215-222, 2001.
 89. Saif, M.W. Wilson, R.H., Harold, N., Keith, B., Dougherty, D.S., and Grem, J.L. Peripheral neuropathy associated with weekly oral fluorouracil, leucovorin and eniluracil. *Anticancer Drugs* 12: 524-531, 2001.
 90. Grem, J.L. Yee, L.K., Schuler, B., Hamilton, J.M., Chen, A.P., Chabuk, C., Grollman, F., Grabenc, M., Allegra, C.J., and Takimoto, C.H. Phosphonacetyl-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72-hours in metastatic gastrointestinal adenocarcinoma. *Ann Oncol* 12: 1581-1587, 2001.
 91. Grem, J.L., Danenberg, K.D., Kao, V., Danenberg, P.V. and Nguyen, D. Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells. *Anticancer Drugs* 13: 259-270, 2002.
 92. Wilson, R.H., Lehky, T. Thomas, R.R., Quinn, M.G., Floeter, M.K., and Grem, J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. *J Clin Oncol* 20: 1767-1774, 2002.
 93. Keith, B., Guo, X-D., Zentko, S., Harold, N., Schuler, B., Quinn, M., Shapiro, J. and Grem, J.L. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition. *Clin Cancer Res* 8: 1045-1050, 2002.
 94. Grem, J.L., Harold, N., Keith, B., Chen, A.P., Kao, V., Takimoto, C.H., Hamilton, J.M., Pang, J., Pace, M., Jasser, G.B., Quinn, M.G., and Monahan, B.P. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients. *Clin Cancer Res* 8: 2149-2156, 2002.
 95. Schmelz, R., Lersch, C., Grem, J.L., Wilson, R., Lehky, T., Thomas, R., Quinn, M., and Floeter, M.K. Acute oxaliplatin-induced peripheral nerve hyperexcitability. *J Clin Oncol* 20: 3561-3562, 2002. [Letter]
 96. Leonard, G.D., Zhuang, S.H., Grem, J.L. Epirubicin, cisplatin and protracted venous-infusion fluorouracil in advanced esophagogastric cancer. *J Clin Oncol* 20:4124-6, 2002 [Letter]
 97. Xu, Y., and Grem, J.L. A liquid chromatography/mass spectroscopy method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma. *J Chromatog B* 783: 273-285, 2003.
 98. Keith, B., Xu, Y., Grem, J.L. Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography. *J Chromatog B* 785: 65-72, 2003.

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

99. Wright, M.A., Schuler, B., Szabo, E., and Grem, J.L. Sustained partial response of intra-abdominal desmoid tumor with gemcitabine, fluorouracil and leucovorin. *Ann Oncol* 14: 659-660, 2003. [Letter]
100. Leonard, G.D., Battiwalla, M., Stockle, J.B., Harris, R.A., Monahan, B.P., and Grem, J.L. Extra-ocular muscle palsy from metastatic pancreatic cancer. *Lancet Oncol* 4:358, 2003. [Clinical Picture]
101. Thomas, R.R., Quinn, M.G., Schuler, B., and Grem, J.L. Hypersensitivity and idiosyncratic reactions to oxaliplatin. *Cancer* 97: 2301-2307, 2003.
102. Guo, X-D., Harold, N., Saif, M.W., Schuler, B., Szabo, E., Hamilton, J.M., Monahan, B.P., Quinn, M.G., Cliatt, J., Nguyen, D., Grollman, F., Thomas, R.R., McQuigan, E.A., Wilson, R., Takimoto, C.H., and Grem, J.L. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. *Cancer Chemother Pharmacol.* 52: 79-85, 2003.
103. Saif, M.W., Quinn, M.G., Thomas, R.R., Ernst A., and Grem, J.L. Cardiac toxicity associated with capecitabine therapy. *Acta Oncol.* 42: 342-344, 2003.
104. Takimoto, C.H., Remick, S.C., Sharma, S., Mani, S., Ramanathan, R.K., Doroshow, J., Hamilton, A., Mulkerin, D., Graham, M., Lockwood, G.F., Ivy, P., Egorin, M., Schuler, B., Greenslade, D., Goetz, A., Knight, R., Thomas, R., Monahan, B.P., Dahut, W., and Grem J.L. A dose escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Group Study. *J Clin Oncol.* 21: 2664-72, 2003
105. Leguizamo, J., Quinn, M., Takimoto, C.H., Liang, M.D., Ismail, A-S.A., Pang, J., Dahut, W., and Grem, J.L. A Phase I Study of 9-Aminocamptothecin as a Colloidal Dispersion Formulation Given as a Fortnightly 72-hour Infusion. *Cancer Chemother Pharmacol.* 52: 333-338, 2003
106. Grem, J.L., Quinn, M.G., Keith, B., Monahan, B.P., Hamilton, J.M., Xu, Y., Harold, N., Nguyen, D., Takimoto, C.H., Rowedder, A., Pang, J., Morrison, G. and Chen A. Phase I trial of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin in adult cancer patients. *Cancer Chemother Pharmacol* 53: 487-496, 2003.
107. Mansky, P.J., Grem, J., Wallerstedt, D.B., Monahan, B.P., and Blackman, M.R. Mistletoe and gemcitabine in patients with advanced cancer: A model for the Phase I study of botanicals and botanical-drug interactions in cancer therapy. *Integrative Cancer Therapies* 2: 345-352, 2003.
108. Xu, Y., Keith, B., and Grem, J.L. Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography and mass spectrometric detection. *J Chromatog B Analyt Technol Biomed Life Sci.* 802:263-70, 2004.
109. Lehky, T.J., Leonard, G.D., Wilson, R.H., Grem, J.L., and Floeter, M.K. Oxaliplatin-induced neurotoxicity: electrophysiologic studies. *Muscle Nerve* 29: 387-392, 2004.
110. Grem, J.L. Mature results of adjuvant colon cancer trials from the fluorouracil-only era. *J Natl Cancer Inst.* 96: 927-929, 2004 (Editorial)
111. Leonard, G.D., Wagner, M.R., Quinn, M.G., Grem, J.L. Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy. *Anticancer Drugs.* 15:733-5., 2004
112. Grem, J.L. Adjuvant therapy for colon cancer: a historical perspective *J Natl Cancer Inst.* 96(15):1116-7, 2004 (Editorial)

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

113. Grem, J.L., Morrison, G., Guo X-D, Agnew E., Takimoto, C.H., Thomas R., Szabo E., Grochow, L., Grollman, F., Hamilton J.M., Neckers L., and Wilson, R.H. A phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. *J Clin Oncol* 23: 1885-93, 2005
114. Ismail A.S., Quinn, M.G., Wright, M.A., Ernst, A., Kao, V., Grogan, L., Parr, A., Grollman, F., Kirsch, I.R. and Grem, J.L. A phase II and pharmacologic study of fluorouracil given by 1-hour infusion daily for five days with leucovorin and interferon α -2a in adenocarcinoma of the large bowel. *Oncol Rep* 13:1145-52, 2005.
115. Wright, M., Morrison, G., Lin, P-X., Leonard, G.D., Nguyen, D., Guo, X.D., Szabo, E., Hopkins, J., Leguizamo, J., Harold, N., Fioravanti, S., Schuler, B., Monahan, B.P., Saif, M.W., Quinn, M.G., Pang, J., and Grem, J.L. A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. *Clin Cancer Res* 11:4144-50, 2005.
116. Grem, J.L. Screening for dihydropyrimidine dehydrogenase deficiency. *Clin Cancer Res* 11: 11:5067-8, 2005. (Editorial).
117. Leonard, G.D., Wright, M.A., Quinn, M.G., Fioravanti, S., Harold, N., Schuler, B., Thomas, R.R., Grem, J.L. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. *BMC Cancer* 5:11, 2005
118. Webster, R.G., Brain, K.L., Wilson, R.H., Grem, J.L., Vincent, A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. *Br J Pharmacol* 146(7):1027-39. 2005
119. Ramanathan, R., Egorin, M.J., Takimoto, C.H.M., Remick, S.C., Doroshow, J.H., LoRusso, P.A., Mulkerin, D., Grem, J.L., Hamilton, A., Murgu, A.J., Potter, D.M., Belani, C.P., Hayes, M.J., Peng, B., Ivy, S.P. A Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction. A study by the National Cancer Institute-Organ Dysfunction Working Group. *J Clin Oncol* (in press, 2007)
120. Takimoto, C.H., Graham, M., Lockwood, G., Ng, C.M., Goetz, A., Greenslade, D., Remick, S.C., Sharma, S., Mani, S., Ramanathan, R.K., Synold, T.W., Doroshow, J. H., Hamilton, A., Mulkerin, D.L., Ivy, P., Egorin, M.J., Grem, J.L. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. *Clin Cancer Res*. (In press, 2007).
121. Gibbons, J., Egorin, M.J., Ramanathan, R.K., Fu, P., Mulkerin, D.L., Shibata, S., Takimoto, C.H.M., Mani, S., LoRusso, P.A., Grem, J.L., Pavlik, A., Lenz, H-J., Flick, S.M., Reynolds, S., Lagutta, T.F., Parise, R.A., Wang, Y., Murgu, A.J., Ivy, S.P., Remick, S.C. A phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction. A study by the National Cancer Institute Organ Dysfunction Working Group. *J Clin Oncol*. (In press, 2007)
122. Uchida, K., Danenberg, P.V., Danenberg, K.D., Grem, J.L. Thymidylate Synthase, Dihydropyrimidine Dehydrogenase, ERCC1, and Thymidine Phosphorylase Gene Expression in Primary and Metastatic Gastrointestinal Adenocarcinoma Tissue in Patients Treated on a Phase I Trial of Oxaliplatin and Capecitabine (Submitted, *BMC Cancer*, 2008)

BIBLIOGRAPHY: PEER-REVIEWED PUBLICATIONS

**APPEARS THIS WAY
ON ORIGINAL**

BIBLIOGRAPHY: BOOK CHAPTERS AND INVITED REVIEW ARTICLES

123. Grem, J.L. and Tormey, D.C.: The chemotherapy of breast cancer, *In: Brain, M.C. and Carbone, P.P. (Eds.), Current Therapy in Hematology/oncology*, B.C. Decker, Inc., Burlington, Ontario, 1985.
124. Grem, J.L. and Carbone, P.P.: Adjuvant hormonotherapy for breast cancer. *European Journal of Cancer and Clinical Oncology* 22: 235-239, 1986.
125. Grem, J.L. and Tormey, D.C.: Chemotherapy in breast cancer, *In: Bayless, T.M., Brain M.C., Cherniak, R.M. (Eds.), Current Therapy in Internal Medicine*, B.C. Decker, Inc., Toronto, Phila, 1987.
126. Grem, J.L.: 5-Fluorouracil plus leucovorin in cancer therapy. *in DeVita, V.T. Jr., Hellman, S., Rosenberg, S.A. (eds): Principles and Practice of Oncology Update Series*, 2(7):1-12, 1988.
127. Allegra, C.J., Grem, J.L., Yeh, G.C., and Chabner, B.A.: Antimetabolites. *In: Pinedo H.M., and Chabner, B.A. (Eds.), Cancer Chemotherapy/10. The Eortc Cancer Chemotherapy Annual*, Elsevier Science Publishers, New York, 1988, pp 1-22.
128. Grem, J.L. and Fischer, P.H.: Enhancement of 5-fluorouracil's anticancer activity by dipyrindamole. *Pharmacology and Therapeutics* 40:349-371, 1989.
129. King, S.A. and Grem, J.L.: Fazarabine. *Drugs of the Future* 14: 20-23, 1989.
130. Grem, J.L., Fluoropyrimidines, *In: Chabner, B.A., Collins, J.M., (Eds.), Pharmacologic Principles of Cancer Treatment*, Second Edition. W.B. Saunders, CO. Philadelphia, 1990, 180-224.
131. Leyland-Jones, B., Chun, H.G., Grem, J.L., Sarosy, G., Dearing, M.P., Christian, M.C., and Henry, W.P.: Investigational New Agents, *In: Chabner, B.A., Collins, J.M. (Eds.), Pharmacologic Principles of Cancer Treatment*, Second Edition. W.B. Saunders, CO. Philadelphia, 1990, 491-530.
132. Allegra, C.J., Grem, J.L., Chu, E., Johnston, P., Yeh, G.C., and Chabner, B.A.: Antimetabolites. *In: Pinedo H.M., Longo, D.L., and Chabner, B.A. (Eds.), Cancer Chemotherapy/11. The Eortc Cancer Chemotherapy Annual*, Elsevier Science Publishers, New York, 1990, pp 1-28.
133. Grem, J.L. Levamisole as a therapeutic agent for colorectal Carcinoma. *Cancer Cells* 2:131-137, 1990.
134. Ahluwalia, G.S., Grem, J.L., Hao, Z., and Cooney, D.A.: Amino Acid Analogs as anticancer agents. *Pharmacology and Therapeutics* 46:243-271, 1990.
135. Grem, J.L. and Allegra, C.J. 5-Fluorouracil plus leucovorin therapy for metastatic breast cancer. *In: Biochemical Modulation, Proceedings of Satellite Symposium held October 25, 1989, Nagoya, Japan, The 27th Annual Meeting of Japan Society for Cancer Therapy, Biomedis, Walsh Japan Co. Inc., Tokyo, 1990, pp 4-12.*
136. Grem, J.L. Current Treatment Approaches in Colorectal Carcinoma. *Seminars in Oncology* 18:(Suppl 1)17-26, 1991.
137. Grem, J.L. Levamisole and 5-fluorouracil in the adjuvant treatment of node-positive colon carcinoma. *Oncology* 5:63-70, 1991
138. Grem, J.L., Chabner, B.A., Chu, E., Johnson, P., Yeh, G.C., and Allegra, C.J. Antimetabolites. *In: Pinedo H.M., Longo, D.L., and Chabner, B.A. (Eds.), Cancer Chemotherapy and Biological Response Modifiers, Annual 12. Elsevier Science Publishers, New York, 1991, p. 1-26.*

BIBLIOGRAPHY: BOOK CHAPTERS AND INVITED REVIEW ARTICLES

139. Grem, J.L. Biochemical modulation of 5-fluorouracil by dipyridamole: preclinical and clinical experience. *Seminars in Oncology* 19 (suppl. 3):56-65, 1992.
140. Grem, J.L., Chu, E., Boarman, D., Balis, F.M., Murphy, R.F., McAtee, N., and Allegra, C.J. Biochemical modulation of 5-fluorouracil with leucovorin and interferon: preclinical and clinical investigations. *Seminars in Oncology* 19 (suppl. 3):36-55, 1992.
141. Grem, J.L. Current therapeutic strategies to enhance 5-fluorouracil activity. *Journal of Infusional Therapy* 2:138-141, 1992.
142. Chu, E., Grem, J.L., Johnson, P.G., Politi, P.M., Chabner, B.A., and Allegra, C.J. Antimetabolites. In: Pinedo H.M., Longo, D.L., and Chabner, B.A. (Eds.), *Cancer Chemotherapy and Biological Response Modifiers, Annual 13*. Elsevier Science Publishers, New York, 1992, pp 1-30.
143. Blaney, S.M., Smith, M.A., and Grem, J.L. Doxorubicin: role in the treatment of osteosarcoma. In: Humphrey, G.B., and Postma, A., (Eds) *Pediatric Oncology, vol. 5: Osteosarcoma- New Developments, Controversies and Current Practice*. Kluwer Academic Publishers, Boston, 1993, p. 55-73.
144. Chen, A.P., and Grem, J.L. Antimetabolites. *Current Opinion in Oncology* 4:1089-1098, 1992.
145. Grem, J.L. Commentary: Update on biochemical modulation of chemotherapeutic agents. *Oncology* 7:110-113, 1993.
146. H. R. Alexander, Grem, J.L., Pass, H.I., Hamilton, M., McAtee, N., Fraker, D.L., Allegra, C.J. Neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma. *Oncology* 7:41, 1993.
147. Chu, E., Johnson, P.G., Takimoto, C.H., Politi, P.M., Grem, J.L., Chabner, B.A., and Allegra, C.J. Antimetabolites. In: Pinedo H.M., Longo, D.L., and Chabner, B.A. (Eds.), *Cancer Chemotherapy and Biological Response Modifiers, Annual 14*. Elsevier Science Publishers, New York, 1993, pp 1-25.
148. Cohen, R.B. and Grem, J.L. Carcinoma of the ovary. In: Foley, J.F., Armitage, J.O., and Vose, J.M., Eds. *CURRENT THERAPY IN ONCOLOGY*. W.B. Saunders Co., Philadelphia, 1994, pp 118-124.
149. Grem, J. Commentary: The Role of Thymidylate Synthase in Predicting Response and Survival in Tumors of the Gastrointestinal Tract. *Journal of Infusional Chemotherapy*. 3: 147-151, 1993.
150. Grem, J., McAtee, N., Drake, J., Steinberg, S., and Allegra, C.J. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-l-aspartate. In: Rustum YM (ed): *Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation. Advances in Experimental Medicine and Biology*, V 339. Plenum Press. New York, 1993. pp 119-123.
151. Geoffroy, F., and Grem, J.L. Chemotherapy of Advanced Gastrointestinal Carcinoma. *Current Opinion in Oncology* 6: 427-434, 1994.
152. Hamilton, J.M., and Grem, J.L. Lower Gastrointestinal Cancer. In: Kirkwood, J.M., Lotze, M.T., and Yasko, J.M. (Eds.) *Current Cancer Therapeutics, First Edition*. Current Medicine. Philadelphia, 1994. pp. 105-109.

BIBLIOGRAPHY: BOOK CHAPTERS AND INVITED REVIEW ARTICLES

153. Chu, E., Johnson, P.G., Grem, J.L., Takimoto, C.H., van Groeningen, C., Chabner, B.A., and Allegra, C.J. Antimetabolites. In: Pinedo H.M., Longo, D.L., and Chabner, B.A. (Eds.), *Cancer Chemotherapy and Biological Response Modifiers*, Annual 15. Elsevier Science Publishers, New York, 1994, pp 1-25.
154. Grem, J., Carvalho, M., Wittes, R.E., and Allegra, C.J. Chemotherapy: The properties and uses of single agents. in: (MacDonald, J.S., Haller, D.G., Mayer, R.J., Eds) *Manual of Oncologic Therapeutics*. Third Edition. J.B. Lippincot Co. Philadelphia. 1995. pp 80-1137.
155. Grem, J.L. Future Challenges for the systemic therapy of metastatic colorectal cancer. *ASCO Educational Book* 1995. pp. 55-58.
156. Grem, J.L., van Groeningen, C.J., Ismail, A.A., Johnston, P.G., Alexander, H.R., and Allegra, C.J. The Role of Interferon α as a Modulator of Fluorouracil and Leucovorin. *European Journal of Cancer* 31A No. 7/8): 1316-1320, 1995.
157. Johnson, P.G., Chu, E., Grem, J.L., Takimoto, C.H., Chabner, B.A., and Allegra, C.J. Antimetabolites. In: Pinedo H.M., Longo, D.L., and Chabner, B.A. (Eds.), *Cancer Chemotherapy and Biological Response Modifiers*, Annual 16. Elsevier Science Publishers, New York, 1995, pp 1-25.
158. Grem, J.L. Fluoropyrimidines. In: Chabner, B.A., Longo, D.L. (Eds.), *Cancer Chemotherapy and Biotherapy: Principles and Practice*, Second Edition. Lippincott-Raven Publishers, Philadelphia., 1996. pp. 149-211.
159. Chu, E., Grem, J.L., Johnston, P.G., and Allegra, C.J. New concepts for the development and use of antifolates. *Stem Cells*. 14: 41-46, 1996.
160. Hamilton, J.M., and Grem, J.L. Lower Gastrointestinal Cancer. In: Kirkwood J.M., Lotze, M.T., Yasko, J.M. (Eds.) *Current Cancer Therapeutics*. Second Edition. Current Medicine. Churchill Livingstone, Philadelphia, 1996; pp 144-153.
161. Takimoto, C.H., Dahut, W., Harold, N., Nakashima, H., Lieberman, R., Liang, M.D., Arbuck, S.G., Chen, A.P., Hamilton, J.M., Cantilena, L.R., Allegra, C.J., and Grem, J.L. Clinical Pharmacology of 9-aminocamptothecin. In Pantazis, P., Giovanella B.C., Rothenberg, M.L. (Eds): *The Camptothecins. From discovery to the patient*. *Annals of the New York Academy of Sciences* v. 803 New York Academy of Sciences, New York, 1996; pp 324-326.
162. Grem, J.L. and Allegra, C.J. Antimetabolites. In: DeVita V.T.Jr., Hellman, S., and Rosenberg, S.A. *Cancer: Principles and Practice of Oncology*. Fifth Edition. Lippincott-Raven Publishers, Philadelphia, 1997; pp 432-452.
163. Johnston, P.G., Takimoto, C.H., Grem, J.L., Fidas, P., Grossbard, M.L., Chabner, B.A., Allegra, C.J., and Chu, E. Antimetabolites. In: Pinedo H.M., Longo, D.L., and Chabner, B.A. (Eds.), *Cancer Chemotherapy and Biological Response Modifiers*, Annual 17. Elsevier Science B.V. New York, 1997, pp 1-39.
164. Grem, J.L. Mechanisms of action and modulation of fluorouracil. *Seminars in Radiation Oncology* 7:249-259, 1997.
165. Grem, J.L. The Prognostic Importance of Tumor Markers in Adenocarcinomas of the Gastrointestinal Tract. *Current Opinion in Oncology* 9: 380-387, 1997.

BIBLIOGRAPHY: BOOK CHAPTERS AND INVITED REVIEW ARTICLES

166. Grem, J.L. Systemic treatment options in advanced colorectal cancer: Perspectives on combination 5-fluorouracil plus leucovorin. *Semin Oncol* 24(suppl 18):S18-8 - S18-18, 1997.
167. Grem, J.L. Recent Insights Into the Molecular Basis of Intrinsic Resistance of Colorectal Cancer: New Challenges for Systemic Therapeutic Approaches. In: Benson, A.B. III (ed): *Cancer Treatment and Research: Gastrointestinal Oncology*. Kluwer Academic Publishers, Norwell, MA, 1998, pp 2293-2338.
168. Shapiro, J., and Grem, J.L. Carcinoma of the Ovary. In: Foley, J.F., Armitage, J.O., and Vose, J.M., Eds. *Current Therapy in Oncology*, second edition. W.B. Saunders Co., Philadelphia 1999, pp 150-157.
169. Grem, J.L., Takimoto, C.H., Multani, P., Chu, E., Ryan, D. Chabner, B.A., Allegra, C.J., and Johnston, P.G. Antimetabolites. In: Pinedo H.M., Longo, D.L., and Chabner, B.A. (Eds.), *Cancer Chemotherapy and Biological Response Modifiers*, Annual 18. Elsevier Science B.V. New York, 1999, pp 1-38.
170. Grem, J.L. 5-Fluorouracil: Forty-Plus and Still Ticking. A Review of Its Preclinical and Clinical Development. *Inv New Drugs* 18: 299-313, 2000.
171. Grem, J.L. The Damjanov/Meropol Article Reviewed (Oral Therapy for Colorectal Cancer: How to Choose). *Oncology* 14: 807-808, 2000.
172. McCarthy, N., and Grem, J.L. Esophageal Cancer. In: Abraham, J., Allegra, C. (Eds). *Handbook of Clinical Oncology*, Lippincott Williams and Wilkins, Philadelphia, 59-69, 2001.
173. Hegde, U., and Grem, J.L. Hepatocellular Carcinoma. In: Abraham, J., Allegra, C. (Eds). *Bethesda Handbook of Clinical Oncology*, Lippincott Williams and Wilkins, Philadelphia, 87-93, 2001.
174. Hegde, U., and Grem, J.L. Biliary Tract Cancer. In: Abraham, J., Allegra, C. (Eds). *Bethesda Handbook of Clinical Oncology*, Lippincott Williams and Wilkins, Philadelphia, 81-86, 2001.
175. Grem, J.L. A Review of Biochemical Modulation of 5-FU as a Strategy in the Systemic Treatment of Advanced Colorectal Cancer. *Oncology (Huntingt)* 15:13-19, 2001.
176. Grem, J.L. Lower Gastrointestinal Cancer. In: Kirkwood J.M., Lotze, M.T., Yasko, J.M. (Eds.) *Current Cancer Therapeutics*. Fourth Edition. Current Medicine, Inc. Philadelphia, 150-162, 2001.
177. Grem, J.L. 5-Fluoropyrimidines. In: Chabner, B.A., Longo, D.L. (Eds.), *Cancer Chemotherapy and Biotherapy: Principles and Practice*, Third Edition. Lippincott-Williams & Wilkins, Philadelphia, 185-254, 2001.
178. Ismail, A-S., and Grem, J.L. Thymidylate Synthase Inhibitors. In Schilsky, R. (Ed) *Cancer Chemotherapy and Biological Response Modifiers*, Annual 19, Elsevier Science 2001, pp 1-19.

BIBLIOGRAPHY: BOOK CHAPTERS AND INVITED REVIEW ARTICLES

179. Grem, J.L. From the Laboratory to the Clinic: The Limitations of Rationally Designed Fluoropyrimidine-Based Therapy and The Problem of Apoptosis-Impaired Cancer Cells. In: Bleiberg H, Kemeny N, Rougier Ph, Wilke H-J (Eds). Colorectal Cancer: A Clinical Guide to Therapy. Martin Dunitz Publishers, London, 399-418, 2002.
180. Grem, J., and Keith, B. Mechanism of action of Cancer Chemotherapeutic Agents: Antimetabolites. In: Alison, M.R. (Editor in Chief) Cancer Handbook, Macmillan Press, London, UK. 2002, pp 1271-1294.
181. Salonga, D., Danenberg, K.D., Grem, J., Park, J.M., Danenberg, P.V. Quantitative RT-PCR for the study of relative gene expression in normal and tumor tissue, in Double JA, Thompson MJ (eds): Telomeres and Telomerases: Methods and Protocols. Methods in Molecular Medicine, vol. 191. Humana Press, 2002. pp 83-98.
182. Grem, J.L. 5-Fluorouracil and its biomodulation in the management of colorectal cancer. In: Saltz, L. (ed), Colorectal Cancer: Multimodality Management. Humana Press, Totowa, NJ 2002: pp 457-0488.
183. Grem, J.L. Ovarian Cancer. In: McCrae, K., Kramer, B.S. (Eds). Hematology-Oncology. MKSAP 13. American College of Physicians, American Society of Internal Medicine, Philadelphia, PA. 2003. pp 113-115.
184. Grem, J.L. Oncologic Emergencies. In: McCrae, K., Kramer, B.S. (Eds). Hematology-Oncology. MKSAP 13. American College of Physicians, American Society of Internal Medicine, Philadelphia, PA. 2003. pp. 115-127
185. Grem, J.L. Pancreatic Cancer. In: McCrae, K., Kramer, B.S. (Eds). Hematology-Oncology. MKSAP 13. American College of Physicians, American Society of Internal Medicine, Philadelphia, PA. 2003, pp 100-104.
186. Grem, J.L. Colorectal Cancer. In: McCrae, K., Kramer, B.S. (Eds). Hematology-Oncology. MKSAP 13. American College of Physicians, American Society of Internal Medicine, Philadelphia, PA. 2003, 78-84.
187. Takimoto, C.H., Remick, S.C., Sharma, S., Mani, S., Ramanathan, R.K., Doroshow, J., Hamilton, A., Mulkerin, D., Graham, M., Lockwood, G.F., Ivy, P., Egorin, M., Schuler, B., Greenslade, D., Goetz, and Grem J.L. Administration of oxaliplatin to patients with impaired renal function: A preliminary report of the National Cancer Institute organ dysfunction working group. Seminars in Oncology 30 (4), suppl 15, 2003.
188. Grem, J.L. The Gowda/Goel/Berdzik et al Article Reviewed (Hypersensitivity reactions to oxaliplatin: incidence and management). Oncology 18: 1676-1680, 2004 (commentary).
189. Grem, J.L. Intratumoral or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. Seminars in Oncology 32: 120-127, 2005.
190. Grem, J.L. The Saltz article reviewed (Metastatic colorectal cancer: Is there one standard approach?). Oncology 19: 1154-1157, 2005 (commentary).
191. Grem, J.L. 5-Fluoropyrimidines. In: Chabner, B.A., Longo, D.L. (Eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, Third Edition. Lippincott-Williams & Wilkins, Philadelphia, 125-179, 2006.

BIBLIOGRAPHY: BOOK CHAPTERS AND INVITED REVIEW ARTICLES

192. Grem, J.L. The Patel and Goldberg article reviewed (Cetuximab-Associated Infusion Reactions: Pathology and Management), Oncology 20 (11), 2006 (commentary).
193. Leonard, G., Grem, J. Colorectal Cancer. In: Boyziadzis, M.M., Lebowitz, P.F, Frame, J.M., Fojo, T. Hematology-Oncology Therapy. McGraw Hill, New York, 101-119, 2007.

**APPEARS THIS WAY
ON ORIGINAL**

INVITED LECTURES: 1995 TO PRESENT

- 1) International Symposium: "Colorectal Cancer: From Gene to Cure", Amsterdam, The Netherlands, Feb. 9-11, 1995. Lecture: "The role of interferon α as a modulator of fluorouracil and leucovorin.
- 2) 31st Annual meeting of the American Society of Clinical Oncology. Los Angeles, CA. May 20-23, 1995. Educational Session: "Regional and systemic therapies for advanced colorectal cancer. Lecture: "Future Challenges for the systemic therapy of metastatic colorectal cancer".
- 3) Berlex Oncology Foundation: Clinical Pharmacology of Anticancer Agents, Leesburg, VA, Oct. 14-17, 1995. Lecture: "Thymidylate Synthase Inhibitors".
- 4) Mini-symposium: Gemcitabine:rationales for Clinical Trial Design and Evaluation". Vrije Universiteit, Amsterdam, The Netherlands, March 12, 1996. Lecture: "The interaction between gemcitabine and fluorodeoxyuridine".
- 5) National Cancer Institute Grand Rounds, Bethesda, MD, February 21, 1996. Lecture: "Future challenges for the systemic therapy of metastatic colorectal cancer".
- 6) _____ Investigators Meeting: A Phase I trial of the _____ formulation of _____ given as a 72 hr continuous infusion every two weeks in adult cancer patients". Philadelphia, PA. May 21, 1996.
- 7) Berlex Oncology Foundation: Clinical Pharmacology of Anticancer Agents, Leesburg, VA, Oct. 5-8, 1996. Lecture: "Thymidylate Synthase Inhibitors"
- 8) USUHS Clinical Pharmacology Lecture Series: "Clinical implications of circadian variation in fluorouracil plasma levels and dihydropyrimidine dehydrogenase activity". December 5, 1996, Bethesda, MD.
- 9) American Society of Clinical Oncology Spring Meeting: Discussant in Gastrointestinal Cancer Poster Discussion Section: "Thymidylate synthase as a prognostic marker and predictor of response to fluorouracil-based therapy". May 18, 1997, Denver, CO
- 10) Investigators meeting organized by Pro-Ed Communications: The Developing Role of Antifolates in Colorectal Cancer. Lecture: "Current Treatment Options in Advanced Colorectal Cancer. Perspectives on 5-fluorouracil and leucovorin". May 29-31, 1997, Turnbury Isle, FL.
- 11) Second World Congress on Advances in Oncology, Oct. 16-18, 1997, Athens, Greece. Lecture: "Future Challenges for the Systemic Treatment of Colorectal Cancer".
- 12) National Cancer Institute Phase I Working Group Meeting, Bethesda, MD, March 10, 1998 "A phase I and pharmacologic trial of pyrazoloacridine, a novel DNA binding agent"
- 13) American Society of Clinical Oncology Spring Meeting: Discussant in Clinical Pharmacology Poster Discussion Section: "Dihydropyrimidine Dehydrogenase as a Therapeutic Target & Oral Fluoropyrimidine Prodrugs". May 25, 1998, Los Angeles, CA
- 14) _____ Regional Advisory Board: "Current systemic chemotherapy options for locally recurrent or metastatic colorectal cancer", Oct. 16-17, 1998, New York, NY.
- 15) NCI CTEP Drug Development Meeting: "A Phase I & pharmacologic trial of a weekly schedule of oral eniluracil (GW 776C85) given with oral fluorouracil and leucovorin". March 23-24, 1999, Bethesda, MD.

- 16) The Third Alexandria Oncology Conference & European School of Oncology Educational Course: Innovations in Cancer Management. Lecture: "Current systemic chemotherapy options for colorectal cancer". October 13 - 15, 1999, Alexandria, Egypt.
- 17) Symposium: Perspectives on Fluorinated Pyrimidine Use in Gastrointestinal and Breast Oncology. "Biochemical modulation of 5-FU". April 17, 2000, New York, NY.
- 18) NCI Symposium for Practicing Physicians: Focus on Colorectal Cancer. "Treatment options for advanced colorectal cancer". April 21, 2001, Bethesda, MD
- 19) American Society of Clinical Oncology Spring Meeting: Discussant in Gastrointestinal Tumors Poster Discussion Section: "Selection of Therapy Based on Molecular Markers". May 13, 2001, San Francisco, CA
- 20) NCI CTEP Drug Development Meeting: "A Phase I pharmacologic trial of 17-AAG". Sept. 24-25, 2001, Bethesda, MD.
- 21) Internal Medicine Grand Rounds: "Systemic Therapy for Advanced Colorectal Cancer". Feb. 25, 2002, Malcolm Grow Hospital, Andrews Air Force Base, VA.
- 22) American Society of Clinical Oncology Spring Meeting: Discussant in Gastrointestinal Tumors Poster Discussion Section: "Chemotherapy for Advanced Colorectal Cancer". May 19, 2002, Orlando, FL
- 23) Army American College of Physicians/American Society of Internal Medicine Annual Meeting: "Pancreatic Cancer Update". Nov. 22, 2002, Alexandria, VA
- 24) Internal Medicine Grand Rounds: "Advances in the Systemic Therapy of Advanced Colorectal Cancer". University of Nebraska Medical Center: May 21, 2004, Omaha, NE
- 25) American Society of Clinical Oncology Annual Meeting: Invited Discussant in Gastrointestinal Tumors Poster Discussion Section: "Prognostic & Predictive Factors for Esophageal and Gastric Cancer". June 8, 2004 New Orleans, FL
- 26) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Symposium: Colon, Rectal & Anal Cancers. "Management of Locoregional Colon Cancer". October 7, 2004. Omaha, NE
- 27) University of Nebraska Medical Center Mini-Medical School: "New approaches to the Treatment of Colorectal Cancer". April 18 2005, Omaha, NE
- 28) Eppley Cancer Center Grand Rounds: A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. November 14, 2005, Omaha, NE
- 29) American Society of Clinical Oncology Annual Meeting: Invited Discussant, Gastrointestinal (Colorectal) Cancer, Oral Session "Discussion of Abstracts 3508-3510". June 5, 2006, Atlanta, GA
- 30) National Naval Medical Center Internal Medicine Grand Rounds: "Primary Management of Colorectal Cancer". June 29, 2006, Bethesda, MD
- 31) Uniformed Services University of the Health Sciences Research Seminar: Examples of Information Gained From Correlative Studies in Phase I Clinical Trials", June 29, 2006, Bethesda, MD

- 32) Walter Reed Army Medical Center Oncology/Hematology Grand Rounds: "Pancreatic Cancer Update", June 20, 2006, Washington, DC
- 33) Roswell Park Cancer Institute, Internal Medicine Grand Rounds "Current treatment options for esophageal cancer". May 25, 2007, Buffalo, NY
- 34) American Society of Clinical Oncology Annual Meeting: Invited Discussant, Gastrointestinal (Colorectal) Cancer, Oral Session "Discussion of Abstracts 4010-4013". June 3, 2007, Chicago, IL
- 35) Great Plains Regional Medical Center Fall Cancer Symposium: "Update on Esophageal Cancer; Update on Colorectal Cancer". Oct. 5, 2007. North Platte, NE
- 36) Ellis Fischel Cancer Center: Oncology Grand Rounds: "Integrating Antibody Therapy in the Treatment of Colorectal Cancer". Nov. 5, 2007. Columbus, MO.

**APPEARS THIS WAY
ON ORIGINAL**